Comparative in-vitro activity of quinupristin/dalfopristin (RP 59500) tested against penicillin-and macrolide-resistant pneumococci by the Etest.
D
D
Biedenbach
A
A
Wanger
R N
RN
Jones
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002981:Clindamycin / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004917:Erythromycin / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests / Q000379:methods*; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D013420:Sulfamethoxazole / Q000494:pharmacology; D014295:Trimethoprim / Q000494:pharmacology; D014769:Virginiamycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D010406:Penicillins; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D002981:Clindamycin; D004917:Erythromycin; D014295:Trimethoprim; D013420:Sulfamethoxazole; D012293:Rifampin